Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Cancer Res. 2021 Jun 24;81(16):4275–4289. doi: 10.1158/0008-5472.CAN-21-0198

Figure 8. Genetically and pharmacologically inhibiting MAOA enhanced antiandrogen drug efficacy.

Figure 8.

(A, B) MTS cell proliferation assays of control and MAOA-KD LNCaP (A) and C4-2 (B) cells by Enz, Daro or Apa at various doses for 5 days (n=3). (C-F) Cell counting assays of LNCaP (C, D) and C4-2 (E, F) cells by Enz, Daro or Apa (5 μM for each) together with clorgyline (1 μM) or phenelzine (2 μM) for 5 days (n=3). Average cell numbers in control group with no treatment were set as 100%. (G) Schematic summarizing MAOA-AR reciprocal interaction in PC. Data represent the mean ± SEM. *p<0.05, **p<0.01.